JCHOR
Journal of Current Hematology & Oncology Research

The Journal of Current Hematology & Oncology Research regularly publishes internationally qualified research in hematology and oncology within the current scholarly knowledge. This journal is indexed by indices that are considered international scientific journal indices (DRJI, ESJI, OAJI, etc.). According to the current Associate Professorship criteria, it is within the scope of International Article 1-d. Each article published in this journal corresponds to 5 points.

ISSN: Active
eISSN: 2980-0854
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Original Article
Factors affecting prognosis in myelodysplastic syndrome: an 11 years’ experience from a tertiary care center
Abstract
Aims: Myelodysplastic syndrome (MDS) is a clonal bone marrow neoplasia characterized by morphological findings of dysplasia in hematopoietic cells, peripheral cytopenia(s), ineffective hematopoiesis, recurrent genetic abnormalities, and an increased risk of conversion to acute myeloid leukemia (AML). The International Prognostic Scoring System (IPSS) is the most commonly used prognostic classification system for MDS. Classification was made by a combination of morphology, cytopenia, and genetic studies. In this study, we aimed to examine the parameters that affect prognosis in MDS patients, show their effects on mortality, and evaluate their positive or negative effects on the course of the disease.
Methods: Two hundred twenty-nine patients who applied to Erciyes University Faculty of Medicine, Department of Hematology, and were diagnosed with MDS according to WHO classification between 2010 and 2020 were included in this retrospective study. Age, gender, additional disease status, laboratory parameters, bone marrow biopsy materials, and genetic mutation analysis data were available. The bone marrow aspiration and biopsy examinations of each patient were evaluated and categorized according to the WHO classification. The prognosis was evaluated according to the data of the patients, survival-exitus, and survival after MDS-AML conversion. Risk scoring was analyzed with three different scoring systems (IPSS, WPSS, and R-IPSS).
Results: Of the 229 MDS patients included in the study, 57% (131) were male. The mean age of the patients was 67 years. Age, MDS-AML conversion times, disease duration, cellularity, and pathology blast rate were found to be statistically significant between the groups (p<0.05). Leukocyte, neutrophil, platelet, hematocrit, lymphocyte, monocyte, CRP, erythropoietin, ferritin, and LDH data were found to be statistically significant regarding survival (p<0.05). Age, IPSS risk status 3, and W-PSS risk status 3 were found to be independent risk factors affecting survival.
Conclusion: Age, IPSS high risk, and WPSS high risk status were found to be independent risk factors affecting survival. Although our study revealed important data in the analysis of MDS patients, single-center analysis of patients and retrospective analysis revealed the need for further studies.

Keywords : Mortality, myelodysplastic syndrome, prognosis

Download Article


1. Pang WW, Pluvinage JV, Price EA, et al. Hematopoietic stem cell andprogenitor cell mechanisms in myelodysplastic syndromes. ProceedNation Acad Sci. 2013;110(8):3011-3016.
2. Moreno Berggren D, Folkvaljon Y, Engvall M, et al. Prognostic scoringsystems for myelodysplastic syndromes (MDS) in a population-basedsetting: a report from the Swedish MDS register. Br J Haematol. 2018;181(5):614-627.
3. Greenberg P, Hoffman R, Benz E, Shattil S. The myelodysplasticsyndromes. Basic Principles and Practice. 3rd ed. Churchill Living-stone: 2000.
4. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The2008 WHO classification of lymphoid neoplasms and beyond: evolvingconcepts and practical applications. Blood. 2011;117(19):5019-5032.
5. van Spronsen MF, Ossenkoppele GJ, Holman R, van de LoosdrechtAA. Improved risk stratification by the integration of the revisedinternational prognostic scoring system with the myelodysplasticsyndromes comorbidity index. Eur J Cancer. 2014;50(18):3198-3205.
6. Groupe Francais de Morphologie Hematologique. French registry ofacute leukemia and myelodysplastic syndromes. Age distribution andhemogram analysis of the 4496 cases recorded during 1982-1983 andclassified according to FAB criteria. Cancer. 1987;60(6):1385-1394.
7. Naqvi K, Jabbour E, Bueso-Ramos C, et al. Implications of discrepancyin morphologic diagnosis of myelodysplastic syndrome betweenreferral and tertiary care centers. Blood. 2011;118(17):4690-4693.
8. Della Porta MG, Malcovati L, Strupp C, et al. Risk stratification basedon both disease status and extra-hematologic comorbidities in patientswith myelodysplastic syndrome. Haematologica. 2011;96(3):441-449.
9. Goldberg SL, Chen E, Corral M, et al. Incidence and clinicalcomplications of myelodysplastic syndromes among United StatesMedicare beneficiaries. J Clin Oncol. 2010;28(17):2847-2852.
10. Sekeres MA, Schoonen WM, Kantarjian H, et al. Characteristics of USpatients with myelodysplastic syndromes: results of six cross-sectionalphysician surveys. J Natl Cancer Inst. 2008;100(21):1542-1551.
11. Ma X, Lim U, Park Y, et al. Obesity, lifestyle factors, and risk ofmyelodysplastic syndromes in a large US cohort. Am J Epidemiol.2009;169(12):1492-1499.
12. Abel GA, Efficace F, Buckstein RJ, et al. Prospective internationalvalidation of the Quality of Life in Myelodysplasia Scale (QUALMS).Haematologica. 2016;101(6):781-788. doi: 10.3324/haematol.2015.140335
13. Sant M, Allemani C, Tereanu C, et al. Incidence of hematologicmalignancies in Europe by morphologic subtype: results of theHAEMACARE project. Blood. 2010;116(19):3724-3734.
14. Bektas O, Uner A, Eliacik E, et al. Comparison of myelodysplasticsyndrome prognostic scoring systems. Turk J Haematol. 2016;33(2):119-126.
15. Della Porta MG, Tuechler H, Malcovati L, et al. Validation ofWHO classification-based Prognostic Scoring System (WPSS)for myelodysplastic syndromes and comparison with the revisedInternational Prognostic Scoring System (IPSS-R). A study of theInternational Working Group for Prognosis in Myelodysplasia (IWG-PM). Leukemia. 2015;29(7):1502-1513.
16. Montalban-Bravo G, Garcia-Manero G. Myelodysplastic syndromes:2018 update on diagnosis, risk-stratification and management. Am JHematol. 2018;93(1):129-147.
17. Hasserjian RP. Myelodysplastic syndrome updated. Pathobiol.2019;86(1):7-13.
18. Strapatsas J, Barbulescu EC, Lauseker M, et al. Influence of plateletcount at diagnosis and during the course of disease on prognosis inMDS patients. Ann Hematol. 2021;100(10):2575-2584.
19. Belohlavkova P, Vrbacky F, Smolej L, et al. Prognostic factors affectingthe outcome after allogeneic haematopoietic stem cell transplantationfor myelodysplastic syndrome. Leuk Res Rep. 2021;16:100274.
20. &Ccedil;elik S, Kaynar L, G&uuml;ven ZT, et al. The effect of danger-associatedmolecular patterns on survival in acute graft versus host disease. BoneMarrow Transplant. 2023;1-7.
21. Almeida A, Fenaux P, List AF, Raza A, Platzbecker U, Santini V. Recentadvances in the treatment of lower-risk non-del(5q) myelodysplasticsyndromes (MDS). Leuk Res. 2017;52:50-57.
22. Malcovati L, Hellstrom-Lindberg E, Bowen D, et al. Diagnosis and treatmentof primary myelodysplastic syndromes in adults: recommendations fromthe European LeukemiaNet. Blood. 2013;122(17):2943-2964.
23. Santini V, Giagounidis A, Pelligra CG, et al. Impact of lenalidomidetreatment on overall survival in patients with lower-risk, transfusion-dependent myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk.2022;22(9):e874-e883.
Article available in :
Volume 2, Issue 1, 2024
Page : 10-14
https://doi.org/10.51271/JCHOR-0028
Article Information
Received : 02 Oca 2024
Accepted : 29 Oca 2024
Published : 12 Şub 2024
Corresponding Author :

Ekrem Küçükoğlu: Department of Internal Medicine, Faculty of Medicine, Erciyes University, Kayseri, Turkiye

[email protected]
Citation : Doğan E, Küçükoğlu E, Keklik M. Factors affecting prognosis in myelodysplastic syndrome: an 11 years’ experience from a tertiary care center. J Curr Hematol Oncol Res. 2024;2(1):10-14.

Read: 450
Cited: 0
Download : 420
_Footer